Developing a new treatment for adenoviral eye infections
Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis
This study is testing a new eye drop treatment for adenoviral conjunctivitis, which is an eye infection that currently has no good options for help, and it's aimed at people who suffer from this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microbiotix, INC NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11037317 on NIH RePORTER |
What this research studies
This research focuses on advancing filociclovir (FCV) as a treatment for adenoviral conjunctivitis and epidemic keratoconjunctivitis, which currently have no effective therapies. The project aims to complete necessary preclinical studies and finalize the formulation of eye drops that can effectively target these infections. By using animal models, the researchers will confirm the efficacy and safety of the treatment before submitting it for FDA approval. This work is crucial as adenoviral infections can lead to significant visual impairment and economic loss.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing symptoms of adenoviral conjunctivitis or epidemic keratoconjunctivitis.
Not a fit: Patients with non-adenoviral eye infections or those who do not have symptoms of conjunctivitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a much-needed effective treatment for patients suffering from adenoviral eye infections.
How similar studies have performed: Previous studies have shown promise in developing antiviral treatments for ocular infections, but this specific approach with filociclovir is novel.
Where this research is happening
Worcester, United States
- Microbiotix, INC — Worcester, United States (Active)
Researchers
- Principal investigator: Bowlin, Terry L. — Microbiotix, INC
- Study coordinator: Bowlin, Terry L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.